The effectiveness of Sulfobenzylpenicillin in the treatment of urinary tract infection was evaluated in the Department of Urology, Seoul National University Hospital during the period from May to November, 1973. Our clinical study was performed on the 28 patients who visited the outpatients clinic and admitted to the ward. These patients were studied by bacterioscopy with Gram's method of staining. and culture in blood agar plate and chocolate agar plate In this studies. the causative organisms were divided into 8 groups; E. coli (5), coagulase positive staphylococcus (5), pseudomonas (2), Corynebacterium spp. (1), a-hemolytic etreptococcus (2), N. Gonorrheae (10), Proteus (2) and KIebsiella (1). The dosage schedule was 1 gm. of Sulfobenzylpenicillin at intervals of 12 hours for consecutive 5 days in gonococcal urethritis and nongonococcal urethritis. But in upper urinary tract infections and post-operative infections, it lasted for 7 to 10 days or more. And following results were obtained. Effectiveness on Urological diseases 1) Gonococcal urethritis; Satisfactory clinical results were obtained with Sulfobenzylpenicillin for five days. Results were excellent in 5 cases, good in 4 cases and negative effect in 1 case. 2) Non-gonococcal urethritis; In this group, the therapeutic results were favorable in 90% of all cases. (excellent-4, good-5, fail-l) 3) Urethral stricture and fistula (2 cases); AII cases were responded to the Sulbenicillin. 4) Cystitis including Prostatism; Two of three cases were caused by E. coli and they had a good response to sulbenicillin. 5) Two cases of pyelonephritis and two cases of postoperative infections were studied with sulbenicillin and more than 60% of cases were effective with sulbenicillin. Side effects were not remarkable but in a few cases who received intramuscular injection, pain on the injection site was noticed.In summary, this new semi-synthetic penicillin is considered to be a useful chemotherapeutic weapon against a variety of infection in the urological field including those due to Gram negative bacilli such as pseudomonas and proteus sp.
Agar ; Appointments and Schedules ; Cacao ; Coagulase ; Corynebacterium ; Cystitis ; Fistula ; Gonorrhea ; Humans ; Injections, Intramuscular ; Outpatients ; Penicillins ; Prostatism ; Proteus ; Pseudomonas ; Pyelonephritis ; Seoul ; Staphylococcus ; Sulbenicillin ; Urethral Stricture ; Urethritis ; Urinary Tract Infections* ; Urinary Tract* ; Urologic Diseases ; Urology

No abstract available.

No abstract available.

No abstract available.
Facial Asymmetry

No abstract available.
Mass Screening* ; Tomography, X-Ray Computed*

Pain from cancer is a major problem of managing the oral cancer patients in terminal stage. Overall, pain is reported by about 50% of patients at all stages of cancer and by over 70% with advanced neoplasms. Unrelieved pain can be incapaciting and preclude a satisfying quality of life. But, pain is often poorly assessed, and many clinicians lack sufficient knowledge to optimize cancer pain treatment. There are three basic approaches to the control of pain : modifying the source of pain, altering the central perception of pain, and blocking the transmission of pain to the central nervous system. The optimal use of these approaches and an individualized plan for pain control can maximize both quality and duration of life in dying patients. Opioid analgesics are are the mainstay of pharmacologic treatment. Practical opioid therapy include selection of both drug and route, dose titration, and management of side effects. We present our experienced pharmacologic treatment protocol for cancer pain management that collaborated by Dept. of Hospice, Catholic Medical Center. It will acts as a guideline for our colleague to facilitate the translation of current knowlegde into the clinical practice.
Analgesics, Opioid ; Central Nervous System ; Clinical Protocols ; Hospices ; Humans ; Mouth Neoplasms* ; Pain Management ; Quality of Life

PURPOSE: Our purpose in this study is to evaluate the effectiveness of bronchial and nonbronchial systemic arteries for the control of hemoptysis. MATERIALS AND METHODS: Seventy patients with massive or recurrent hemoptysis underwent percutaneous transcatheter embolotherapy between 1991 and 1993. Retrospectively we reviewed 77 cases of bronchial artery embotization and 32 cases of nonbronchial systemic artery embolization in the 70 patients. RESULTS: Immdiate control of hemoptysis was achieved in 33 of 39 patients with massive hemoptysis(84.6%) and 20 of 24 patients with recurrent hemopt ysis(83.3%). In 32 cases, nonbronchial systemic arteries contributed significantly to areas of pathologic pulmonary tissue and frequently were the major arterial supply. CONCLUSION: Bronchial artery embolization is an effective and life saving procedure in non-surgical candidates. Recognition and occlusion of nonbronchial systemic arteries that feed to hypervascular pulmonary lesions is essential for successful percutaneous embolotherapy of hemoptysis.
Arteries ; Bronchial Arteries ; Embolization, Therapeutic ; Hemoptysis* ; Humans ; Retrospective Studies

No abstract available.
Electric Stimulation*

Abscess ; Age Distribution ; Cardiovascular Diseases ; Dental Caries ; Drainage ; Endocrine System Diseases ; Female ; Humans ; Jeollabuk-do ; Korea ; Liver ; Male ; Periodontal Diseases ; Prognosis ; Retrospective Studies ; Surgery, Oral ; Tooth Extraction

The purpose of this study is to compare the efficacy and safety of 0.25 and 0.5mg/ml of mitomycin C(MMC) on the outcome of glaucoma filtration surgery in eyes undergoing primary trabeculectomy. Twenty-eight eyes of 20 patients with primary open-angle glaucoma or primary angle-closure glaucoma, who underwent primary trabeculectomy with 0.25mg/ml MMC for 3 minutes were compared with a demographically similar group of 31 eyes of 22 patients with primary open-angle glaucoma or primary angle-closure glaucoma, who had undergone primary trabeculectomy with 0.5mg/ml MMC for 3 minutes. MMC was applied between the sclera and Tenon's capsule during trabeculectomy, and scleral flap was closed with tight releasable sutures. The mean preoperative intraocular pressure was 35.2 +/- 9.3mmHg in the 0.25mg group and 32.1 +/- 9.2mmHg in the 0.5mg group(p=0.21, Student's unpaired t-test). The mean number of preoperative medications was 2.7 +/- 0.9 and 2.7 +/- 0.8(p=0.92, Mann Whitney U test), respectively. No statistically significant differences were found in mean intraocular pressures between the two groups at the three. six, and nine months postoperative periods. The mean follow-up was 9.2 months in the 0.25mg group and 9.0 months in the 0.5mg group(p=0.82, Student's unpaired t-test). At the last postoperative visit. 89%(25 eyes) in the 0.25mg group and 97%(30 eyes) in the 0.5mg group had an intraocular pressure less than 21mmHg with or without glaucoma medication(p=0.50, Fisher exact test). The mean intraocular pressures were 16.0 +/- 6.9mmHg and 13.6 +/- 3.6mmHg, respectively (p=0.10, Student's unpaired t-test). The 0.25mg group received an average of 0.5 medications for IOP control, and the 0.5mg group received an average of 0.2 medications(p=0.32, Mann Whitney U test). The postoperative visual outcome of the two groups did not differ significantly(p=0.27, Fisher exact test). There was no significant difference in complications between the two groups. Hypotony developed in one eye in the 0.5mg group. These results suggest that using 0.25 and 0.5mg/ml MMC for 3 minutes in primary trabeculectomy yields similar results in terms of efficacy and safety.
Filtering Surgery ; Follow-Up Studies ; Glaucoma* ; Glaucoma, Angle-Closure ; Glaucoma, Open-Angle ; Humans ; Intraocular Pressure ; Mitomycin* ; Postoperative Period ; Sclera ; Sutures ; Tenon Capsule ; Trabeculectomy*